{"slug":"zoetis","name":"조에티스","name_en":"Zoetis Inc.","ticker":"ZTS","updated_at":"2026-09-24T03:12:37.120538+00:00","canonical":"https://valuechain.wiki/zoetis","citable":"밸류체인 그래프 기준 조에티스의 직접 연결 기업은 2곳(관계 기준 공급 0·매출 1·투자 1)이고, 사슬을 2차까지 넓히면 16곳에 닿는다. 링크의 근거 출처는 10건이며 그중 1차공시가 4건이다 (valuechain.wiki, 2026-09-24 기준).","citable_en":"Per the valuechain.wiki graph, Zoetis Inc. is directly linked to 2 companies (0 supply, 1 revenue, 1 investment relationships) and reaches 16 companies within two hops; the links are backed by 10 dated sources, 4 of them primary filings (as of 2026-09-24).","kicker":"동물의약품 선도기업","kicker_en":"Animal health medicines leader","lead":"조에티스는 반려동물과 가축용 의약품, 백신, 진단 제품을 수의사와 축산업자에게 판매하며 대형 동물의약품 유통사를 중요한 판매 경로로 쓴다. 자체 생산시설과 외부 위탁생산망을 함께 운영하고, 항체 발굴 기술과 조달 시스템에도 비용을 쓴다.","lead_en":"Zoetis sells medicines, vaccines and diagnostics for companion animals and livestock to veterinarians and producers, using large animal-health distributors as an important route to market. It combines an internal manufacturing network with external manufacturing and spends on antibody-discovery technology and procurement infrastructure.","categories":[{"key":"pharma-biotech","ko":"제약·바이오텍","en":"Pharmaceuticals & Biotechnology","theme":"life-sciences","theme_ko":"바이오·헬스","theme_en":"Biopharma & Life Sciences","theme_kind":"sector","primary":true}],"segments":{"parts":[{"name":"미국","note":"FY2025 매출 50억9,700만달러"},{"name":"해외","note":"FY2025 매출 42억5,400만달러"},{"name":"위탁생산·인체의약","note":"FY2025 매출 1억1,600만달러"}],"total":"FY2025 총매출 94억6,700만달러","track":"C"},"segments_en":{"parts":[{"name":"United States","note":"FY2025 revenue of $5.097 billion"},{"name":"International","note":"FY2025 revenue of $4.254 billion"},{"name":"Contract manufacturing and human health","note":"FY2025 revenue of $116 million"}],"total":"FY2025 total revenue of $9.467 billion"},"returns_yearly":{"2021":48.3,"2022":-39.5,"2023":35.9,"2024":-16.6,"2025":-21.8,"2026":-39.6},"return_asof":"2026-10-09","value_chain":{"leading":[{"slug":"cencora","name":"센코라","name_en":"Cencora, Inc.","tier":1,"returns_yearly":{"2021":44.1,"2022":26.3,"2023":25.3,"2024":10.4,"2025":51.5,"2026":-1.4}}],"benefiting":[{"slug":"blackrock","name":"BlackRock","name_en":"BlackRock","tier":1,"returns_yearly":{"2021":29.4,"2022":-20.4,"2023":17.9,"2024":29.3,"2025":6.6,"2026":2.8}},{"slug":"marathon-petroleum","name":"마라톤 페트롤리엄","name_en":"Marathon Petroleum Corporation","tier":2,"returns_yearly":{"2021":61,"2022":86.6,"2023":30.5,"2024":-4.1,"2025":19.2,"2026":183}},{"slug":"targa-resources","name":"타가 리소시스","name_en":"Targa Resources Corp.","tier":2,"returns_yearly":{"2021":100.1,"2022":43.7,"2023":21,"2024":110.1,"2025":5.7,"2026":59.5}},{"slug":"altria","name":"알트리아","name_en":"Altria Group, Inc.","tier":2,"returns_yearly":{"2021":24.2,"2022":4.4,"2023":-3.7,"2024":40.8,"2025":18.2,"2026":30.3}},{"slug":"ross-stores","name":"로스 스토어스","name_en":"Ross Stores","tier":2,"returns_yearly":{"2021":-6,"2022":2.9,"2023":20.6,"2024":10.4,"2025":20.4,"2026":28.6}},{"slug":"oneok","name":"원오크","name_en":"ONEOK, Inc.","tier":2,"returns_yearly":{"2021":64.7,"2022":18.9,"2023":13.2,"2024":50.1,"2025":-22.9,"2026":26.8}},{"slug":"elevance-health","name":"엘레반스 헬스","name_en":"Elevance Health, Inc.","tier":2,"returns_yearly":{"2021":46.1,"2022":11.8,"2023":-6.9,"2024":-20.7,"2025":-3.1,"2026":17.4}},{"slug":"old-dominion","name":"올드 도미니언","name_en":"Old Dominion Freight Line, Inc.","tier":2,"returns_yearly":{"2021":84.1,"2022":-20.5,"2023":43.5,"2024":-12.5,"2025":-10.5,"2026":16.5}},{"slug":"incyte","name":"인사이트","name_en":"Incyte Corporation","tier":2,"returns_yearly":{"2021":-15.6,"2022":9.4,"2023":-21.8,"2024":10,"2025":43,"2026":14.2}},{"slug":"american-water-works","name":"아메리칸 워터 웍스","name_en":"American Water Works","tier":2,"returns_yearly":{"2021":24.8,"2022":-17.9,"2023":-11.7,"2024":-3.5,"2025":7.4,"2026":10.1}},{"slug":"edwards-lifesciences","name":"에드워즈 라이프사이언스","name_en":"Edwards Lifesciences Corporation","tier":2,"returns_yearly":{"2021":42,"2022":-42.4,"2023":2.2,"2024":-2.9,"2025":15.2,"2026":5.5}},{"slug":"hubbell-incorporated","name":"허벨","name_en":"Hubbell Incorporated","tier":2,"returns_yearly":{"2021":35.6,"2022":15.1,"2023":42.4,"2024":28.9,"2025":7.4,"2026":4.7}},{"slug":"microsoft","name":"마이크로소프트","name_en":"Microsoft","tier":2,"returns_yearly":{"2021":52.5,"2022":-28,"2023":58.2,"2024":12.9,"2025":15.6,"2026":4}},{"slug":"edison-international","name":"에디슨 인터내셔널","name_en":"Edison International","tier":2,"returns_yearly":{"2021":13.6,"2022":-2.6,"2023":17.4,"2024":15.2,"2025":-20.4,"2026":-1.7}},{"slug":"public-service-enterprise-group","name":"퍼블릭 서비스 엔터프라이즈 그룹","name_en":"Public Service Enterprise Group Incorporated","tier":2,"returns_yearly":{"2021":18.3,"2022":-5.1,"2023":3.6,"2024":42.6,"2025":-1.9,"2026":-6.7}},{"slug":"seagate","name":"Seagate","name_en":"Seagate Technology","tier":3,"returns_yearly":{"2021":87.5,"2022":-51.4,"2023":69.1,"2024":4.1,"2025":225.3,"2026":209.1}},{"slug":"amd","name":"AMD","name_en":"AMD","tier":3,"returns_yearly":{"2021":56.9,"2022":-55,"2023":127.6,"2024":-18.1,"2025":77.3,"2026":183.9}},{"slug":"nebius","name":"Nebius","name_en":"Nebius Group","tier":3,"returns_yearly":{"2025":202.2,"2026":170.5}},{"slug":"marvell","name":"Marvell","name_en":"Marvell","tier":3,"returns_yearly":{"2021":84.6,"2022":-57.5,"2023":63.7,"2024":83.8,"2025":-22.8,"2026":163.4}},{"slug":"intel","name":"Intel","name_en":"Intel","tier":3,"returns_yearly":{"2021":6.1,"2022":-46.6,"2023":94.6,"2024":-59.6,"2025":84,"2026":159.6}},{"slug":"western-digital","name":"Western Digital","name_en":"Western Digital","tier":3,"returns_yearly":{"2021":17.7,"2022":-51.6,"2023":66,"2024":13.9,"2025":283.7,"2026":130.9}},{"slug":"astera-labs","name":"Astera Labs","name_en":"Astera Labs","tier":3,"returns_yearly":{"2025":25.6,"2026":105.7}},{"slug":"wiwynn","name":"Wiwynn","name_en":"Wiwynn","tier":3,"returns_yearly":{"2021":24.7,"2022":-22.3,"2023":206.4,"2024":3.5,"2025":64.4,"2026":92.3}},{"slug":"vertiv","name":"Vertiv","name_en":"Vertiv","tier":3,"returns_yearly":{"2021":33.8,"2022":-45.3,"2023":251.8,"2024":136.8,"2025":42.8,"2026":73.2}},{"slug":"ge-vernova","name":"GE Vernova","name_en":"GE Vernova","tier":3,"returns_yearly":{"2025":99,"2026":54}},{"slug":"tsmc","name":"TSMC","name_en":"TSMC","tier":3,"returns_yearly":{"2021":12.1,"2022":-36.7,"2023":42.3,"2024":92.6,"2025":55.9,"2026":50.3}},{"slug":"occidental-petroleum","name":"옥시덴탈 페트롤리엄","name_en":"Occidental Petroleum","tier":3,"returns_yearly":{"2021":67.7,"2022":119.1,"2023":-4.1,"2024":-15.9,"2025":-14.9,"2026":48.2}},{"slug":"arista","name":"Arista Networks","name_en":"Arista Networks","tier":3,"returns_yearly":{"2021":97.9,"2022":-15.6,"2023":94.1,"2024":87.7,"2025":18.5,"2026":47.9}},{"slug":"sumitomo-electric","name":"Sumitomo Electric","name_en":"Sumitomo Electric","tier":3,"returns_yearly":{"2021":11.4,"2022":6.3,"2023":30.8,"2024":52.9,"2025":139,"2026":43.2}},{"slug":"super-micro","name":"Super Micro","name_en":"Super Micro","tier":3,"returns_yearly":{"2021":38.8,"2022":86.8,"2023":246.2,"2024":7.2,"2025":-4,"2026":43}},{"slug":"archer-daniels-midland","name":"아처 대니얼스 미들랜드","name_en":"Archer-Daniels-Midland Company","tier":3,"returns_yearly":{"2021":37.3,"2022":40,"2023":-20.4,"2024":-27.5,"2025":18.2,"2026":41.8}},{"slug":"caterpillar","name":"Caterpillar","name_en":"Caterpillar","tier":3,"returns_yearly":{"2021":16,"2022":18.6,"2023":25.9,"2024":24.7,"2025":60.3,"2026":40.6}},{"slug":"state-street","name":"스테이트 스트리트","name_en":"State Street Corporation","tier":3,"returns_yearly":{"2021":31,"2022":-13.8,"2023":3.5,"2024":30.2,"2025":35.5,"2026":38.8}},{"slug":"ciena","name":"Ciena","name_en":"Ciena","tier":3,"returns_yearly":{"2021":45.6,"2022":-33.8,"2023":-11.7,"2024":88.4,"2025":175.8,"2026":37.3}},{"slug":"equinix","name":"Equinix","name_en":"Equinix","tier":3,"returns_yearly":{"2021":20.3,"2022":-21.1,"2023":25.4,"2024":19.5,"2025":-16.9,"2026":37.3}},{"slug":"eaton","name":"Eaton","name_en":"Eaton","tier":3,"returns_yearly":{"2021":46.7,"2022":-7.2,"2023":56.2,"2024":39.5,"2025":-2.8,"2026":36}},{"slug":"philip-morris-international","name":"필립 모리스 인터내셔널","name_en":"Philip Morris International Inc.","tier":3,"returns_yearly":{"2021":20.8,"2022":12.3,"2023":-1.9,"2024":34.3,"2025":38,"2026":28.7}},{"slug":"cvs-health","name":"CVS 헬스","name_en":"CVS Health","tier":3,"returns_yearly":{"2021":54.9,"2022":-7.6,"2023":-12.5,"2024":-40.8,"2025":84.3,"2026":24.7}},{"slug":"digital-realty","name":"Digital Realty","name_en":"Digital Realty","tier":3,"returns_yearly":{"2021":30.7,"2022":-41,"2023":39.9,"2024":35.9,"2025":-10.1,"2026":23.4}},{"slug":"nvidia","name":"NVIDIA","name_en":"NVIDIA","tier":3,"returns_yearly":{"2021":125.5,"2022":-50.3,"2023":239,"2024":171.2,"2025":38.9,"2026":23.2}},{"slug":"becton-dickinson","name":"벡톤 디킨슨","name_en":"Becton, Dickinson and Company","tier":3,"returns_yearly":{"2021":1.9,"2022":5.1,"2023":-2.7,"2024":-5.4,"2025":-12.6,"2026":22.8}},{"slug":"quanta","name":"Quanta","name_en":"Quanta Computer","tier":3,"returns_yearly":{"2021":22.2,"2022":-12.8,"2023":254.5,"2024":12.7,"2025":8.9,"2026":21.2}},{"slug":"federal-realty-investment-trust","name":"페더럴 리얼티 인베스트먼트 트러스트","name_en":"Federal Realty Investment Trust","tier":3,"returns_yearly":{"2021":66,"2022":-22.7,"2023":6.6,"2024":12.1,"2025":-5.9,"2026":19.8}},{"slug":"credo","name":"크레도","name_en":"Credo Technology","tier":3,"returns_yearly":{"2023":46.3,"2024":245.2,"2025":114.1,"2026":18.5}},{"slug":"abb","name":"ABB","name_en":"ABB","tier":3,"returns_yearly":{"2021":23.9,"2022":7.3,"2023":18.9,"2024":39,"2025":36.1,"2026":18.4}},{"slug":"iren","name":"IREN","name_en":"IREN","tier":3,"returns_yearly":{"2022":-92.3,"2023":472,"2024":37.3,"2025":284.6,"2026":18.3}},{"slug":"foxconn","name":"Foxconn","name_en":"Foxconn (Hon Hai)","tier":3,"returns_yearly":{"2021":-5.1,"2022":2.8,"2023":7.8,"2024":80.1,"2025":26.9,"2026":16.3}},{"slug":"coreweave","name":"CoreWeave","name_en":"CoreWeave","tier":3,"returns_yearly":{"2026":14.6}},{"slug":"kuraray","name":"구라레","name_en":"Kuraray","tier":3,"returns_yearly":{"2021":-4.9,"2022":8.7,"2023":50.1,"2024":51,"2025":-24.7,"2026":12.5}},{"slug":"amazon","name":"아마존","name_en":"Amazon","tier":3,"returns_yearly":{"2021":2.4,"2022":-49.6,"2023":80.9,"2024":44.4,"2025":5.2,"2026":12}},{"slug":"schneider-electric","name":"Schneider Electric","name_en":"Schneider Electric","tier":3,"returns_yearly":{"2021":25.9,"2022":1.6,"2023":25.8,"2024":36.1,"2025":0.5,"2026":11.7}},{"slug":"simon-property-group","name":"사이먼 프로퍼티 그룹","name_en":"Simon Property Group","tier":3,"returns_yearly":{"2021":95.7,"2022":-21.9,"2023":29.2,"2024":26.9,"2025":12.9,"2026":11.4}},{"slug":"cummins","name":"Cummins","name_en":"Cummins","tier":3,"returns_yearly":{"2021":-1.7,"2022":14.1,"2023":1.7,"2024":48.9,"2025":49.4,"2026":11}},{"slug":"automatic-data-processing","name":"오토매틱 데이터 프로세싱","name_en":"Automatic Data Processing, Inc.","tier":3,"returns_yearly":{"2021":42.6,"2022":-1.3,"2023":-0.2,"2024":28.4,"2025":-10.2,"2026":9.6}},{"slug":"3m","name":"3M","name_en":"3M Company","tier":3,"returns_yearly":{"2021":4.9,"2022":-29.6,"2023":-3.3,"2024":46.1,"2025":26.4,"2026":6.8}},{"slug":"legrand","name":"르그랑","name_en":"Legrand","tier":3,"returns_yearly":{"2021":20.3,"2022":-7.1,"2023":12.8,"2024":11.9,"2025":39.3,"2026":6.1}},{"slug":"nxp","name":"NXP반도체","name_en":"NXP Semiconductors","tier":3,"returns_yearly":{"2021":44.8,"2022":-29.2,"2023":48.4,"2024":-8,"2025":6.4,"2026":5.9}},{"slug":"expedia-group","name":"익스피디아 그룹","name_en":"Expedia Group, Inc.","tier":3,"returns_yearly":{"2021":36.5,"2022":-51.5,"2023":73.3,"2024":22.8,"2025":53.3,"2026":5.8}},{"slug":"wec-energy-group","name":"WEC 에너지 그룹","name_en":"WEC Energy Group","tier":3,"returns_yearly":{"2021":8.7,"2022":-0.5,"2023":-7,"2024":16.1,"2025":16,"2026":3.1}},{"slug":"cheryong-electric","name":"제룡전기","name_en":"Cheryong Electric","tier":3,"returns_yearly":{"2021":-14.1,"2022":141.8,"2023":89.3,"2024":178.6,"2025":-9.3,"2026":-1}},{"slug":"taihan-cable-solution","name":"대한전선","name_en":"Taihan Cable & Solution","tier":3,"returns_yearly":{"2021":59.3,"2022":-0.7,"2023":-36,"2024":40.6,"2025":124.6,"2026":-4.4}},{"slug":"apollo-global-management","name":"아폴로 글로벌 매니지먼트","name_en":"Apollo Global Management","tier":3,"returns_yearly":{"2021":53.2,"2022":-9.6,"2023":49.4,"2024":79.9,"2025":-11.1,"2026":-6.5}},{"slug":"lg-chem","name":"LG화학","name_en":"LG Chem","tier":3,"returns_yearly":{"2021":-29,"2022":9.7,"2023":-36.6,"2024":-45.3,"2025":31.2,"2026":-8.6}},{"slug":"brookfield","name":"Brookfield","name_en":"Brookfield Asset Management Ltd.","tier":3,"returns_yearly":{"2023":45.6,"2024":39.7,"2025":-0.2,"2026":-9.7}},{"slug":"ionq","name":"IonQ","name_en":"IonQ","tier":3,"returns_yearly":{"2022":-79.3,"2023":259.1,"2024":237.1,"2025":7.4,"2026":-11.9}},{"slug":"tesla","name":"Tesla","name_en":"Tesla","tier":3,"returns_yearly":{"2021":49.8,"2022":-65,"2023":101.7,"2024":62.5,"2025":11.4,"2026":-14.9}},{"slug":"constellation-energy","name":"Constellation Energy","name_en":"Constellation Energy","tier":3,"returns_yearly":{"2023":37.2,"2024":92.7,"2025":58.8,"2026":-15.3}},{"slug":"take-two-interactive","name":"테이크투 인터랙티브","name_en":"Take-Two Interactive Software, Inc.","tier":3,"returns_yearly":{"2021":-14.5,"2022":-41.4,"2023":54.6,"2024":14.4,"2025":39.1,"2026":-16.6}},{"slug":"openai","name":"OpenAI","name_en":"OpenAI","tier":3,"returns_yearly":null}],"analysis":"동물의약품 선도기업. 2025년 -21.8%, 2026년 -38.8%로 약세가 이어진다. 수요단(평균 -1.4%)이 본주(-38.8%)를 앞서 있어 고객 쪽 움직임이 먼저 가는 구도다.","analysis_en":"Zoetis Inc. operates across Animal health medicines leader. It remained weak at -21.8% in 2025 and -38.8% in 2026. The demand side (avg -1.4%) leads the stock (-38.8%), so customer moves come first here. It combines an internal manufacturing network with external manufacturing and spends on antibody-discovery technology and procurement infrastructure.","analysis_asof":"2026-09-04"},"edges":[{"direction":"investor","counterparty":"BlackRock","counterparty_slug":"blackrock","confidence":"high","metric":{"type":"share","unit":"%","as_of":"2026-07-30","basis":"BlackRock의 조에티스 수익적 보유 지분율","value":9,"period":"As of 2026-06-30","basis_en":"BlackRock beneficial ownership of Zoetis","qualifier":null},"note":"BlackRock은 2026년 6월 30일 기준 조에티스 주식 3,766만315주를 수익적 보유해 지분율 9.0%를 공시했다. 공시는 경영권 영향 목적이 아닌 통상적 투자 보유라고 설명한다.","note_en":"BlackRock reported beneficial ownership of 37,660,315 Zoetis shares, or 9.0%, as of June 30, 2026. The filing states that the shares were held in the ordinary course rather than to influence control.","sources":[{"stance":"confirms","publisher":"SEC EDGAR","publisher_en":"SEC EDGAR","kind":"filing","lang":"en","published_at":"2026-07-30","url":"https://www.sec.gov/Archives/edgar/data/1555280/000201238326003137/xslSCHEDULE_13G_X02/primary_doc.xml","title":"BlackRock Schedule 13G/A for Zoetis Inc.","title_en":"BlackRock Schedule 13G/A for Zoetis Inc.","excerpt":"BlackRock은 조에티스 주식 3,766만315주를 수익적 보유하며 발행 주식의 9.0%라고 신고했다.","excerpt_en":"Aggregate Amount Beneficially Owned: 37,660,315. Percent of class: 9.0%."}]},{"direction":"cost","counterparty":"Trianni","counterparty_slug":null,"confidence":"high","metric":{"type":"amount","unit":"USD","as_of":"2020-07-07","basis":"Trianni 항체 발굴 플랫폼 협업 대가","value":null,"period":"Agreement announced 2020","basis_en":"Consideration for the Trianni antibody-discovery platform collaboration","qualifier":"confirmed_no_disclosed_value"},"note":"조에티스는 동물용 단일클론항체 후보를 발굴하기 위해 Trianni의 형질전환 항체 플랫폼 개발 역량을 도입했다. 계약 금액은 공개되지 않았다.","note_en":"Zoetis engaged Trianni's transgenic antibody-platform capabilities to support discovery of monoclonal antibody candidates for veterinary treatments. Financial terms were not disclosed.","sources":[{"stance":"confirms","publisher":"Zoetis","publisher_en":"Zoetis","kind":"ir","lang":"en","published_at":"2020-07-07","url":"https://news.zoetis.com/press-releases/press-release-details/2020/Trianni-and-Zoetis-Announce-Agreement-to-Develop-a-Transgenic-Antibody-Discovery-Platform-for-Use-in-Animal-Health/default.aspx","title":"Trianni and Zoetis Announce Agreement to Develop a Transgenic Antibody Discovery Platform for Use in Animal Health","title_en":"Trianni and Zoetis Announce Agreement to Develop a Transgenic Antibody Discovery Platform for Use in Animal Health","excerpt":"조에티스와 Trianni는 새로운 동물 치료제 발굴을 위한 형질전환 단일클론항체 플랫폼 개발 협업을 발표했으며 재무 조건은 공개하지 않았다.","excerpt_en":"Trianni, Inc. and Zoetis announced a collaboration for the development of transgenic monoclonal antibody platforms for the discovery of new veterinary treatments."}]},{"direction":"cost","counterparty":"SAP","counterparty_slug":null,"confidence":"high","metric":{"type":"amount","unit":"USD","as_of":"2015-04-27","basis":"SAP ERP·Ariba 조달 인프라 사용 대가","value":null,"period":"From 2015","basis_en":"Consideration for SAP ERP and Ariba procurement infrastructure","qualifier":"confirmed_no_disclosed_value"},"note":"조에티스는 미국 조직의 ERP와 구매 주문·전자 송장 처리를 SAP 및 Ariba Supplier Network로 운영한다. 소프트웨어 사용료는 공개되지 않았다.","note_en":"Zoetis runs ERP, purchase-order and electronic-invoicing workflows for its U.S. organization on SAP and the Ariba Supplier Network. Software fees are not disclosed.","sources":[{"stance":"confirms","publisher":"Zoetis","publisher_en":"Zoetis","kind":"ir","lang":"en","published_at":"2014-03-13","url":"https://www.zoetis.com/global-assets/private/supplier-communication-letter_us.pdf","title":"Zoetis U.S. Supplier Communication Letter","title_en":"Zoetis U.S. Supplier Communication Letter","excerpt":"조에티스는 미국 조직을 새 SAP ERP로 전환하고 Ariba Supplier Network를 구매 주문과 전자 송장 처리에 사용한다고 공급사에 공지했다.","excerpt_en":"Beginning April 27th, 2015 Zoetis is moving to new ERP system (SAP) for the US organization. The PO format will change, and be sent via the Ariba Supplier Network."}]},{"direction":"investment","counterparty":"Veterinary Pathology Group","counterparty_slug":null,"confidence":"high","metric":{"type":"amount","unit":"USD","as_of":"2025-11-11","basis":"Veterinary Pathology Group 인수 대가","value":null,"period":"2025 acquisition","basis_en":"Consideration for the acquisition of Veterinary Pathology Group","qualifier":"confirmed_no_disclosed_value"},"note":"조에티스는 2025년 영국·아일랜드의 수의 진단검사 기업 Veterinary Pathology Group을 인수해 진단 사업을 확대했다. 인수 금액은 공개되지 않았고 재무제표에 중대한 영향을 주지 않았다.","note_en":"Zoetis acquired Veterinary Pathology Group, a veterinary diagnostic laboratory business in the U.K. and Ireland, in 2025 to expand diagnostics. The purchase price was not disclosed, and the transaction was not material to its financial statements.","sources":[{"stance":"confirms","publisher":"SEC EDGAR","publisher_en":"SEC EDGAR","kind":"filing","lang":"en","published_at":"2026-02-12","url":"https://www.sec.gov/Archives/edgar/data/1555280/000155528026000011/zts-20251231.htm","title":"Zoetis Inc. 2025 Annual Report on Form 10-K","title_en":"Zoetis Inc. 2025 Annual Report on Form 10-K","excerpt":"조에티스는 2025년 영국과 아일랜드에 여러 거점을 둔 VPG를 인수했으며 거래가 연결재무제표에 중대한 영향을 주지 않았다고 공시했다.","excerpt_en":"During 2025, we acquired Veterinary Pathology Group (VPG), a leading veterinary diagnostic laboratory group with multiple locations across the U.K. and Ireland."},{"stance":"confirms","publisher":"Zoetis","publisher_en":"Zoetis","kind":"ir","lang":"en","published_at":"2025-11-11","url":"https://investor.zoetis.com/news/news-details/2025/Zoetis-Acquires-Veterinary-Pathology-Group-to-Strengthen-Veterinary-Diagnostics-in-UK-and-Ireland-2025-a3nQiAH0s9/default.aspx","title":"Zoetis Acquires Veterinary Pathology Group to Strengthen Veterinary Diagnostics in UK and Ireland","title_en":"Zoetis Acquires Veterinary Pathology Group to Strengthen Veterinary Diagnostics in UK and Ireland","excerpt":"조에티스는 영국과 아일랜드의 수의 진단검사 그룹 VPG 인수를 발표했다.","excerpt_en":"Zoetis Inc. announced the acquisition of Veterinary Pathology Group (VPG), a leading veterinary diagnostic laboratory group with multiple locations across the UK and Ireland."}]},{"direction":"revenue","counterparty":"센코라","counterparty_slug":"cencora","confidence":"mid","metric":{"type":"revenue_share","unit":"%","as_of":"2026-02-12","basis":"MWI·센코라 경로에서 발생한 조에티스 매출 비중","value":null,"period":"FY2025","basis_en":"Share of Zoetis revenue generated through the MWI/Cencora channel","qualifier":"confirmed_no_disclosed_value"},"note":"센코라가 보유한 MWI Animal Health는 조에티스 제품을 미국 수의 시장에 유통한다. 조에티스 10-K는 최대 미국 수의 유통사가 FY2025 매출의 16%라고 공시했지만 고객명을 밝히지 않았으므로, 이 16%를 센코라 매출로 단정하지 않는다.","note_en":"Cencora-owned MWI Animal Health distributes Zoetis products into the U.S. veterinary market. Zoetis disclosed that its largest U.S. veterinary distributor represented 16% of FY2025 revenue, but did not name that customer, so the 16% is not attributed to Cencora here.","sources":[{"stance":"confirms","publisher":"SEC EDGAR","publisher_en":"SEC EDGAR","kind":"filing","lang":"en","published_at":"2026-02-12","url":"https://www.sec.gov/Archives/edgar/data/1555280/000155528026000011/zts-20251231.htm","title":"Zoetis Inc. 2025 Annual Report on Form 10-K","title_en":"Zoetis Inc. 2025 Annual Report on Form 10-K","excerpt":"조에티스는 최대 고객인 미국 수의 유통사가 2025년 총매출의 약 16%를 차지했다고 공시했으나 회사명은 공개하지 않았다.","excerpt_en":"Sales to our largest customer, a U.S. veterinary distributor, represented approximately 16% of total revenue for 2025."},{"stance":"mentions","publisher":"초이스스탁US","publisher_en":"ChoiceStock US","kind":"analysis","lang":"ko","published_at":"2025-09-17","url":"https://www.choicestock.co.kr/stock/research_view/6571","title":"[분석] 조에티스(ZTS), 화이자에서 독립한 글로벌 펫 의약품 1위 기업","title_en":"Analysis: Zoetis, the Global Pet-Medicine Leader Spun Out of Pfizer","excerpt":"분석은 조에티스 매출의 68%가 반려동물 의약품에서 나오며 미국이 가장 큰 시장이라고 설명한다. 이는 미국 수의 유통 경로의 사업 중요성을 뒷받침한다.","excerpt_en":"The analysis says companion-animal products generate 68% of Zoetis revenue and the United States is its largest market, supporting the importance of the U.S. veterinary distribution channel."},{"stance":"confirms","publisher":"SEC EDGAR","publisher_en":"SEC EDGAR","kind":"filing","lang":"en","published_at":"2015-01-12","url":"https://www.sec.gov/Archives/edgar/data/1323974/000110465915001992/a15-2249_3ex99d1.htm","title":"AmerisourceBergen Call to Discuss Acquisition of MWI Veterinary Supply","title_en":"AmerisourceBergen Call to Discuss Acquisition of MWI Veterinary Supply","excerpt":"AmerisourceBergen은 MWI 인수 설명회에서 MWI의 가장 큰 공급사가 조에티스라고 밝혔다.","excerpt_en":"If you look at some of our largest vendors, the biggest would be Zoetis."},{"stance":"confirms","publisher":"SEC EDGAR","publisher_en":"SEC EDGAR","kind":"filing","lang":"en","published_at":"2013-11-27","url":"https://www.sec.gov/Archives/edgar/data/1323974/000132397413000039/mwiv-20130930x10k.htm","title":"MWI Veterinary Supply, Inc. 2013 Annual Report on Form 10-K","title_en":"MWI Veterinary Supply, Inc. 2013 Annual Report on Form 10-K","excerpt":"MWI는 2013년 조에티스가 매출 기준 자사의 최대 공급사라고 공시했다.","excerpt_en":"In 2013, Pfizer completed the spin off its animal health business as Zoetis, which is now our largest vendor, measured by revenues."}]},{"direction":"revenue","counterparty":"Covetrus","counterparty_slug":null,"confidence":"mid","metric":{"type":"revenue_share","unit":"%","as_of":"2026-05-01","basis":"Covetrus 유통 경로에서 발생한 조에티스 매출 비중","value":null,"period":"FY2025","basis_en":"Share of Zoetis revenue generated through the Covetrus distribution channel","qualifier":"confirmed_no_disclosed_value"},"note":"Covetrus는 조에티스의 가축용 구충제, 항균제, 백신과 호르몬 제품을 자사 주문 카탈로그에 싣고 수의 고객에게 유통한다. 상대별 거래액은 공개되지 않았다.","note_en":"Covetrus lists Zoetis livestock parasiticides, anti-infectives, vaccines and hormone products in its ordering catalog for veterinary customers. Transaction value by counterparty is not disclosed.","sources":[{"stance":"mentions","publisher":"뉴스1","publisher_en":"News1 Korea","kind":"news","lang":"ko","published_at":"2026-05-01","url":"https://v.daum.net/v/y1vi9PmjYb","title":"신동엽 \"따져 봐야죠\"…올인원 구충제 심패리카 트리오 영상 공개","title_en":"Zoetis Unveils Simparica Trio Campaign Featuring Shin Dong-yup","excerpt":"심패리카 트리오는 동물병원에서 수의사가 처방하는 조에티스의 올인원 구충제이며, 한국조에티스는 리브렐라와 솔렌시아도 판매하고 있다.","excerpt_en":"Simparica Trio is a Zoetis all-in-one parasiticide prescribed by veterinarians at animal hospitals, and Zoetis Korea also sells Librela and Solensia."},{"stance":"confirms","publisher":"Covetrus","publisher_en":"Covetrus","kind":"ir","lang":"en","published_at":"2020-03-01","url":"https://northamerica.covetrus.com/docs/default-source/landing-pages/cov_20eqls95-covetrus-2020-livestock-preferred-product-guide-042120.pdf?sfvrsn=55026d73_2","title":"Covetrus Livestock Preferred Product Guide","title_en":"Covetrus Livestock Preferred Product Guide","excerpt":"Covetrus 제품 가이드는 Dectomax, Valbazen, Liquamycin, Draxxin, Lutalyse 등 여러 조에티스 제품을 주문 가능한 품목으로 열거한다.","excerpt_en":"The Covetrus product guide lists multiple Zoetis products, including Dectomax, Valbazen, Liquamycin, Draxxin and Lutalyse, as orderable selections."}]}]}